ArticleERJ open research2024

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2.

Martin Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.